The U.S. Federal Circuit affirmed the validity of three patents protecting Exelixis’s Cabometyx (cabozantinib), securing the company’s exclusivity and expected delaying generic competition by at least three more years. Exelixis said the decision strengthens its defense against generic efforts initiated through MSN Pharmaceuticals’ infringement challenge based on written description arguments. Cabometyx is a blockbuster in oncology, and patent durability remains a key driver of cash flow and pipeline planning for large oncology portfolios. A patent win of this type can also influence how payers and compounding or biosimilar-adjacent pathways are managed at the pharmacy level. For Exelixis, the ruling provides more certainty around the near-term competitive landscape and supports longer-term planning for subsequent line extensions and next-generation assets.